Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) appointed Eric Hedrick as chief medical officer, the company announced. Hedrick will report to CEO Henry Gosebruch and join the management committee.

The appointment supports the company's transformation following its acquisition of Ouro Medicines operational assets announced on June 4, 2026. Hedrick joined Lakefront in July 2025 as clinical evaluation lead for new pipeline opportunities.

"Eric has been an invaluable contributor over this past year, driving our clinical assessments and partnering with our external colleagues," Gosebruch said. "The Ouro portfolio is now the cornerstone of Lakefront's R&D pipeline and I'm thrilled to have a talented drug developer of Eric's caliber and experience to guide the development of gamgertamig and our future clinical programs."

Hedrick brings 25 years of pharmaceutical and biotechnology experience. He previously served as chief executive physician at EQRx, chief advisor and interim chief medical officer for BeiGene, chief medical officer at Epizyme, and interim chief medical officer at Pharmacyclics. He began his biotechnology career at Genentech.

Hedrick received his medical degree from the University of Maryland and served as an attending physician at Memorial Sloan-Kettering Cancer Center.